Home
About Us
Pancreatic Cancer
Safety
News
Partnerships
Investor Relations
Expanded Access
…
Home
About Us
Pancreatic Cancer
Safety
News
Partnerships
Investor Relations
Expanded Access
Home
About Us
Pancreatic Cancer
Safety
News
Partnerships
Investor Relations
Expanded Access
…
Home
About Us
Pancreatic Cancer
Safety
News
Partnerships
Investor Relations
Expanded Access
News
Recent news on Salspera
SALSPERA ANNOUNCES INCREASE in SURVIVAL of STAGE 4 PANCREATIC CANCER PATIENTS TREATED with IMMUNOTHERAPY, SALTIKVA®.
January 5, 2023
Cambridge, MA (January 5, 2023) - Salspera is announcing positive results from its Phase 2 study...
FDA GRANTS FAST TRACK DESIGNATION TO SALSPERA'S SALTIKVA, AN INNOVATIVE IMMUNOTHERAPEUTIC APPROACH TO TREAT METASTATIC PANCREATIC CANCER
June 1, 2022
Salspera today announced the U.S. Food and Drug Administration (FDA) granted Fast Track...
FDA GRANTS ORPHAN DRUG DESIGNATION (ODD) TO SALSPERA'S SALTIKVA, AN INNOVATIVE IMMUNOTHERAPEUTIC APPROACH TO TREAT METASTATIC PANCREATIC CANCER
May 23, 2022
Salspera today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug...
Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Accept
Learn More